|
[1]
|
Yang, K., Wu, Z., Zhang, H., Zhang, N., Wu, W., Wang, Z., et al. (2022) Glioma Targeted Therapy: Insight into Future of Molecular Approaches. Molecular Cancer, 21, Article No. 39.
https://doi.org/10.1186/s12943-022-01513-z
|
|
[2]
|
Yalamarty, S.S.K., Filipczak, N., Li, X., Subhan, M.A., Parveen, F., Ataide, J.A., et al. (2023) Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM). Cancers, 15, Article No. 2116.
https://doi.org/10.3390/cancers15072116
|
|
[3]
|
Fei, X., Wu, J., Tian, H., Jiang, D., Chen, H., Yan, K., et al. (2024) Glioma Stem Cells Remodel Immunotolerant Microenvironment in GBM and Are Associated with Therapeutic Advancements. Cancer Biomarkers, 41, 1-24.
https://doi.org/10.3233/cbm-230486
|
|
[4]
|
Jezierzański, M., Nafalska, N., Stopyra, M., Furgoł, T., Miciak, M., Kabut, J., et al. (2024) Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme—A Literature Review and Clinical Outcomes. Current Oncology, 31, 3994-4002.
https://doi.org/10.3390/curroncol31070296
|
|
[5]
|
Tomar, M.S., Kumar, A., Srivastava, C. and Shrivastava, A. (2021) Elucidating the Mechanisms of Temozolomide Resistance in Gliomas and the Strategies to Overcome the Resistance. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1876, Article ID: 188616.
https://doi.org/10.1016/j.bbcan.2021.188616
|
|
[6]
|
Eckerdt, F. and Platanias, L.C. (2023) Emerging Role of Glioma Stem Cells in Mechanisms of Therapy Resistance. Cancers, 15, Article No. 3458.
https://doi.org/10.3390/cancers15133458
|
|
[7]
|
Banelli, B., Carra, E., Barbieri, F., Würth, R., Parodi, F., Pattarozzi, A., et al. (2015) The Histone Demethylase KDM5A Is a Key Factor for the Resistance to Temozolomide in Glioblastoma. Cell Cycle, 14, 3418-3429.
https://doi.org/10.1080/15384101.2015.1090063
|
|
[8]
|
Rabé, M., Dumont, S., Álvarez-Arenas, A., Janati, H., Belmonte-Beitia, J., Calvo, G.F., et al. (2020) Identification of a Transient State during the Acquisition of Temozolomide Resistance in Glioblastoma. Cell Death & Disease, 11, Article No. 19.
https://doi.org/10.1038/s41419-019-2200-2
|
|
[9]
|
Richalet, J., Hermand, E. and Lhuissier, F.J. (2024) Cardiovascular Physiology and Pathophysiology at High Altitude. Nature Reviews Cardiology, 21, 75-88.
https://doi.org/10.1038/s41569-023-00924-9
|
|
[10]
|
Gil del Alcazar, C.R., Todorova, P.K., Habib, A.A., Mukherjee, B. and Burma, S. (2016) Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma. Molecular Cancer Research, 14, 928-940.
https://doi.org/10.1158/1541-7786.mcr-16-0125
|
|
[11]
|
Fedele, M., Cerchia, L., Pegoraro, S., Sgarra, R. and Manfioletti, G. (2019) Proneural-Mesenchymal Transition: Phenotypic Plasticity to Acquire Multitherapy Resistance in Glioblastoma. International Journal of Molecular Sciences, 20, Article No. 2746.
https://doi.org/10.3390/ijms20112746
|
|
[12]
|
Qu, S., Qi, S., Zhang, H., Li, Z., Wang, K., Zhu, T., et al. (2023) Albumin-Bound Paclitaxel Augment Temozolomide Treatment Sensitivity of Glioblastoma Cells by Disrupting DNA Damage Repair and Promoting Ferroptosis. Journal of Experimental & Clinical Cancer Research, 42, Article No. 285.
https://doi.org/10.1186/s13046-023-02843-6
|
|
[13]
|
Shaw, R., Basu, M., Karmakar, S. and Ghosh, M.K. (2024) MGMT in TMZ-Based Glioma Therapy: Multifaceted Insights and Clinical Trial Perspectives. Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, 1871, Article ID: 119673.
https://doi.org/10.1016/j.bbamcr.2024.119673
|
|
[14]
|
Della Monica, R., Cuomo, M., Buonaiuto, M., Costabile, D., Franca, R.A., Del Basso De Caro, M., et al. (2022) MGMT and Whole-Genome DNA Methylation Impacts on Diagnosis, Prognosis and Therapy of Glioblastoma Multiforme. International Journal of Molecular Sciences, 23, Article No. 7148.
https://doi.org/10.3390/ijms23137148
|
|
[15]
|
Lassman, A.B., Pugh, S.L., Wang, T.J.C., Aldape, K., Gan, H.K., Preusser, M., et al. (2022) Depatuxizumab Mafodotin in EGFR-Amplified Newly Diagnosed Glioblastoma: A Phase III Randomized Clinical Trial. Neuro-Oncology, 25, 339-350.
https://doi.org/10.1093/neuonc/noac173
|
|
[16]
|
Lin, K., Gueble, S.E., Sundaram, R.K., Huseman, E.D., Bindra, R.S. and Herzon, S.B. (2022) Mechanism-Based Design of Agents That Selectively Target Drug-Resistant Glioma. Science, 377, 502-511.
https://doi.org/10.1126/science.abn7570
|
|
[17]
|
Cheng, X., An, J., Lou, J., Gu, Q., Ding, W., Droby, G.N., et al. (2024) Trans-Lesion Synthesis and Mismatch Repair Pathway Crosstalk Defines Chemoresistance and Hypermutation Mechanisms in Glioblastoma. Nature Communications, 15, Article No. 1957.
https://doi.org/10.1038/s41467-024-45979-5
|
|
[18]
|
Hong, B., Yang, E., Su, D., Ju, J., Cui, X., Wang, Q., et al. (2024) EPIC-1042 as a Potent PTRF/Cavin1-caveolin-1 Interaction Inhibitor to Induce PARP1 Autophagic Degradation and Suppress Temozolomide Efflux for Glioblastoma. Neuro-Oncology, 26, 100-114.
https://doi.org/10.1093/neuonc/noad159
|
|
[19]
|
Omuro, A., Brandes, A.A., Carpentier, A.F., Idbaih, A., Reardon, D.A., Cloughesy, T., et al. (2022) Radiotherapy Combined with Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma with Unmethylated mgmt Promoter: An International Randomized Phase III Trial. Neuro-Oncology, 25, 123-134.
https://doi.org/10.1093/neuonc/noac099
|
|
[20]
|
Bora, A., Majhi, B., Palit, S., Patra, R. and Dutta, S. (2025) Disrupting the Base Excision Repair (BER) Pathway by Targeting the Abasic Site Enhances the Sensitivity of PARP Inhibitor in HR-Proficient Cancer Cells. ACS Chemical Biology, 20, 1863-1874.
https://doi.org/10.1021/acschembio.5c00022
|
|
[21]
|
Chen, J., Liu, G., Wang, X., Hong, H., Li, T., Li, L., et al. (2022) Glioblastoma Stem Cell-Specific Histamine Secretion Drives Pro-Angiogenic Tumor Microenvironment Remodeling. Cell Stem Cell, 29, 1531-1546.e7.
https://doi.org/10.1016/j.stem.2022.09.009
|
|
[22]
|
Xu, X., Zheng, Y., Luo, L., You, Z., Chen, H., Wang, J., et al. (2024) Glioblastoma Stem Cells Deliver ABCB4 Transcribed by ATF3 via Exosomes Conferring Glioblastoma Resistance to Temozolomide. Cell Death & Disease, 15, Article No. 318.
https://doi.org/10.1038/s41419-024-06695-6
|
|
[23]
|
Yan, Y., Cheng, Y., Li, Y., Jiao, X., Liu, Y., Cai, H., et al. (2023) Inhibitor of Wnt Receptor 1 Suppresses the Effects of Wnt1, Wnt3a and β-Catenin on the Proliferation and Migration of C6 GSCs Induced by Low-Dose Radiation. Oncology Reports, 51, Article No. 22.
https://doi.org/10.3892/or.2023.8681
|
|
[24]
|
Cheng, C., Cui, L., Cui, X., Zhan, Q., Ju, J., Hong, B., et al. (2025) ADAM12 Promotes Temozolomide Resistance in Glioblastoma by Activating the TNF-α-NF-κB Pathway. Cancer Letters, 620, Article ID: 217684.
https://doi.org/10.1016/j.canlet.2025.217684
|
|
[25]
|
Li, J., Garavaglia, S., Ye, Z., Moretti, A., Belyaeva, O.V., Beiser, A., et al. (2021) A Specific Inhibitor of ALDH1A3 Regulates Retinoic Acid Biosynthesis in Glioma Stem Cells. Communications Biology, 4, Article No. 1420.
https://doi.org/10.1038/s42003-021-02949-7
|
|
[26]
|
Chen, Z., Wang, J., Peng, P., Liu, G., Dong, M., Zhang, X., et al. (2024) Hypoxia-Induced TGFBI Maintains Glioma Stem Cells by Stabilizing EphA2. Theranostics, 14, 5778-5792.
https://doi.org/10.7150/thno.95141
|
|
[27]
|
Yoshioka, M., Noguchi, S., Iwadate, Y., Kobayashi, M., Motohashi, S. and Higuchi, Y. (2025) MGMT Promoter Methylation in Glioblastoma Stem Cells: Stability during Differentiation and Comparison with Surgically-Resected Tumors. Anticancer Research, 45, 4959-4969.
https://doi.org/10.21873/anticanres.17839
|
|
[28]
|
Jiang, M.Q., Yu, S.P., Estaba, T., Choi, E., Berglund, K., Gu, X., et al. (2024) Reprogramming Glioblastoma Cells into Non-Cancerous Neuronal Cells as a Novel Anti-Cancer Strategy. Cells, 13, Article No. 897.
https://doi.org/10.3390/cells13110897
|
|
[29]
|
Cui, X., Zhao, J., Li, G., Yang, C., Yang, S., Zhan, Q., et al. (2023) Blockage of EGFR/AKT and Mevalonate Pathways Synergize the Antitumor Effect of Temozolomide by Reprogramming Energy Metabolism in Glioblastoma. Cancer Communications, 43, 1326-1353.
https://doi.org/10.1002/cac2.12502
|
|
[30]
|
Yan, Y., Zhou, S., Chen, X., Yi, Q., Feng, S., Zhao, Z., et al. (2024) Suppression of ITPKB Degradation by Trim25 Confers TMZ Resistance in Glioblastoma through ROS Homeostasis. Signal Transduction and Targeted Therapy, 9, Article No. 58.
https://doi.org/10.1038/s41392-024-01763-x
|
|
[31]
|
Zeng, Y., Zhao, L., Zeng, K., Zhan, Z., Zhan, Z., Li, S., et al. (2025) TRAF3 Loss Protects Glioblastoma Cells from Lipid Peroxidation and Immune Elimination via Dysregulated Lipid Metabolism. Journal of Clinical Investigation, 135, e178550.
https://doi.org/10.1172/jci178550
|
|
[32]
|
Veeramachaneni, R.K., Suter, R.K., Rowland, E., Jermakowicz, A. and Ayad, N.G. (2024) Glutaminase 2 as a Therapeutic Target in Glioblastoma. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1879, Article ID: 189182.
https://doi.org/10.1016/j.bbcan.2024.189182
|
|
[33]
|
Bady, P., Marosi, C., Weller, M., Grønberg, B.H., Schultz, H., Taphoorn, M.J.B., et al. (2022) DNA Methylation-Based Age Acceleration Observed in IDH Wild-Type Glioblastoma Is Associated with Better Outcome—Including in Elderly Patients. Acta Neuropathologica Communications, 10, Article No. 39.
https://doi.org/10.1186/s40478-022-01344-5
|
|
[34]
|
Ye, L., Gu, L., Wang, Y., Xing, H., Li, P., Guo, X., et al. (2024) Identification of TMZ Resistance‐Associated Histone Post-Translational Modifications in Glioblastoma Using Multi-Omics Data. CNS Neuroscience & Therapeutics, 30, e14649.
https://doi.org/10.1111/cns.14649
|
|
[35]
|
Upadhyay, R., Sethy, B., Yang, W., Wu, M., Liou, K., Wu, A., et al. (2025) A Novel Dual CDC25-HDAC Inhibitor Suppresses Glioblastoma Progression via Chromosomal Passenger Complex Disruption. Biomedicine & Pharmacotherapy, 193, Article ID: 118816.
https://doi.org/10.1016/j.biopha.2025.118816
|
|
[36]
|
Ho, K., Hsu, S., Chen, P., Cheng, C., Liu, A., Chien, M., et al. (2025) Hypoxia Enhances IL-8 Signaling through Inhibiting miR-128-3p Expression in Glioblastomas. Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, 1872, Article ID: 119885.
https://doi.org/10.1016/j.bbamcr.2024.119885
|
|
[37]
|
Ercelik, M., Tekin, C., Pamukcu, A., Gurbuz, M., Karaman, D.S. and Tunca, B. (2026) Oleuropein-and Hydroxytyrosol-Loaded Nanoparticles: A Novel Strategy against Glioblastoma Aggressiveness. Naunyn-Schmiedeberg’s Archives of Pharmacology, 399, 3055-3071.
https://doi.org/10.1007/s00210-025-04621-x
|
|
[38]
|
de Souza, I., Monteiro, L.K.S., Guedes, C.B., Silva, M.M., Andrade-Tomaz, M., Contieri, B., et al. (2022) High Levels of NRF2 Sensitize Temozolomide-Resistant Glioblastoma Cells to Ferroptosis via ABCC1/MRP1 Upregulation. Cell Death & Disease, 13, Article No. 591.
https://doi.org/10.1038/s41419-022-05044-9
|
|
[39]
|
Amirinejad, M., Eftekhar-Vaghefi, S.H., Nematollahi Mahani, S.N., Salari, M., Yahyapour, R. and Ahmadi-Zeidabadi, M. (2024) Exposure to Low-Frequency Radiation Changes the Expression of Nestin, VEGF, BCRP and Apoptosis Markers during Glioma Treatment Strategy: An in Vitro Study. Current Radiopharmaceuticals, 17, 55-67.
https://doi.org/10.2174/0118744710258350230921065159
|
|
[40]
|
Gürsoy, G.T., Tuncer, M.C. and Özdemir, İ. (2025) Resveratrol and Temozolomide Induce Apoptosis and Suppress Proliferation in Glioblastoma Cells via the Apoptotic Signaling Pathway. Acta Cirúrgica Brasileira, 40, e405525.
https://doi.org/10.1590/acb405525
|
|
[41]
|
Zhao, K., Braun, M., Meyer, L., Otte, K., Raifer, H., Helmprobst, F., et al. (2024) A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1. Cells, 13, Article No. 632.
https://doi.org/10.3390/cells13070632
|
|
[42]
|
Yin, H.T., Hui, L., Yang, J.H., et al. (2024) Daurisoline Suppress Glioma Progression by Inhibiting Autophagy through PI3K/AKT/mTOR Pathway and Increases TMZ Sensitivity. Biochemical Pharmacology, 223, Article ID: 116113.
https://doi.org/10.1016/j.bcp.2024.116113
|
|
[43]
|
Miao, Z., Xu, L., Gu, W., Ren, Y., Li, R., Zhang, S., et al. (2024) A Targetable PRR11-DHODH Axis Drives Ferroptosis-And Temozolomide-Resistance in Glioblastoma. Redox Biology, 73, Article ID: 103220.
https://doi.org/10.1016/j.redox.2024.103220
|
|
[44]
|
Xue, Y., Lu, Y., Sun, G., Fang, F., Ji, Y., Tang, H., et al. (2022) CN‐3 Increases TMZ Sensitivity and Induces ROS‐Dependent Apoptosis and Autophagy in TMZ‐Resistance Glioblastoma. Journal of Biochemical and Molecular Toxicology, 36, e22973.
https://doi.org/10.1002/jbt.22973
|
|
[45]
|
Zhang, H., Chen, Y., Liu, X. and Deng, H. (2023) Multi-Omics Analyses Reveal Mitochondrial Dysfunction Contributing to Temozolomide Resistance in Glioblastoma Cells. Biomolecules, 13, Article No. 1408.
https://doi.org/10.3390/biom13091408
|
|
[46]
|
Fan, Q., Chen, H., Wei, G., Wei, D., Wang, Z., Zhang, L., et al. (2025) A Review of Conjugation Technologies for Antibody Drug Conjugates. Antibody Therapeutics, 8, 157-170.
https://doi.org/10.1093/abt/tbaf010
|